Objectif Personalized medicine aspires to provide optimal therapy in real-time during patient treatment, however current methodology falls short to deliver this in a robust manner. With this in mind, we invented a method for the screening of thousands of drug responses in small samples of an individual’s peripheral blood by automated microscopy and single-cell image analysis. We termed this method pharmacoscopy. In the course of carrying out the i-FIVE ERC grant project plan, we began screening for novel anti-viral or immune modulating drugs. In the quest to increase the physiological relevance of our screening settings, we investigated the possibility of using peripheral blood cells or bone marrow from individuals. We have thus far been able to show that the approach allows for the screening of anti-inflammatory properties of compounds, and to score for distinct sub-population specific cell cytotoxicity profiles of clinical anti-neoplastic agents through the tracking of fluorescent antibodies and probes. Moreover, we have been able to show that the approach empowers the therapeutic decision-making capability of hema-oncologists in a concrete clinical setting using primary myelofibrosis and lymphoma as test diseases. With funding from this grant, we intend to obtain further clinical data through retrospective trials, and incorporate the results into an information package attractive enough to draw the attention of potential investors. We have secured the intellectual property rights and have assembled the know-how required to enable commercialization efforts. With the unique image-based single cell analysis of human liquid tissues, we believe that chemos has the potential to develop into a service that enables and advances personalized medicine and drug discovery for a broad spectrum of hematological disorders. Champ scientifique medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverynatural sciencesphysical sciencesopticsmicroscopymedical and health scienceshealth sciencespersonalized medicinemedical and health sciencesclinical medicinehematology Programme(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Thème(s) ERC-PoC-2016 - ERC-Proof of Concept-2016 Appel à propositions ERC-2016-PoC Voir d’autres projets de cet appel Régime de financement ERC-POC - Proof of Concept Grant Institution d’accueil CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH Contribution nette de l'UE € 146 668,00 Adresse LAZARETTGASSE 14 AKH BT 25.3 1090 Wien Autriche Voir sur la carte Région Ostösterreich Wien Wien Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 146 668,00 Bénéficiaires (1) Trier par ordre alphabétique Trier par contribution nette de l'UE Tout développer Tout réduire CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH Autriche Contribution nette de l'UE € 146 668,00 Adresse LAZARETTGASSE 14 AKH BT 25.3 1090 Wien Voir sur la carte Région Ostösterreich Wien Wien Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 146 668,00
